Zobrazeno 1 - 10
of 502
pro vyhledávání: '"Clifford E. Kashtan"'
Autor:
Clifford E. Kashtan
Publikováno v:
American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 190:399-403
Alport syndrome is an inherited disorder of the kidneys that results from variants in three collagen IV genes-COL4A3, COL4A4, and COL4A5. Early diagnosis and pharmacologic intervention can delay the progression of chronic kidney disease and the onset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a6d243daa166c5ac7a6c9c3980bb4a1
https://doi.org/10.1002/ajmg.c.31987
https://doi.org/10.1002/ajmg.c.31987
Autor:
Clifford E. Kashtan
Publikováno v:
Journal of Multidisciplinary Healthcare
Alport syndrome is a multisystem disorder that universally affects the kidney and frequently involves the inner ear and the eye. Over the course of a lifetime, addressing the health care needs of a person with Alport syndrome and their family entails
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e829ed71979878bfaafb419aac3abb57
https://doi.org/10.2147/jmdh.s284784
https://doi.org/10.2147/jmdh.s284784
Autor:
Oliver Gross, Clifford E. Kashtan
Publikováno v:
Pediatric Nephrology. 36:711-719
In 2013, we published a set of clinical practice recommendations for the treatment of Alport syndrome in this journal. We recommended delaying the initiation of angiotensin-converting enzyme inhibition until the onset of overt proteinuria or, in some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f5038e6d9116dcba2b274fb58555780
https://doi.org/10.1007/s00467-020-04819-6
https://doi.org/10.1007/s00467-020-04819-6
Autor:
Clifford E. Kashtan
Publikováno v:
Expert Opinion on Orphan Drugs. 8:179-188
This review presents an approach to early diagnosis and treatment of Alport syndrome, an important genetic cause of kidney failure, with the goal of delaying the need for dialysis and kidney transp...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d63f51a8df1ffb89ad6e429eb0a8776c
https://doi.org/10.1080/21678707.2020.1784722
https://doi.org/10.1080/21678707.2020.1784722
Autor:
Melanie P. Chin, Sripal Bangalore, Bradley A. Warady, Colin J. Meyer, Gerald B. Appel, Arnold L. Silva, Clifford E. Kashtan, Laura H. Mariani, Roser Torra, Pablo E. Pergola, Kazumoto Iijima, Geoffrey A. Block, Rajiv Agarwal, Kandai Nozu, Keisha L. Gibson, Lesley A. Inker, Michelle N. Rheault, Peter Stenvinkel, Glenn M. Chertow, Angie Goldsberry, Sharon Andreoli, Bertrand Knebelmann, Megan O'Grady, Arlene B. Chapman
Publikováno v:
Clinical journal of the American Society of Nephrology : CJASN. 17(12)
Alport syndrome is an inherited disease characterized by progressive loss of kidney function. We aimed to evaluate the safety and efficacy of bardoxolone methyl in patients with Alport syndrome.We randomly assigned patients with Alport syndrome, ages
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcc5b1ac783c260e49f6de162f262075
https://pubmed.ncbi.nlm.nih.gov/36411058
https://pubmed.ncbi.nlm.nih.gov/36411058
Publikováno v:
Clinical nephrology. 97(3)
Registry data from Europe has shown an increase in age at end-stage kidney disease for patients with Alport syndrome in recent years. Whether a similar delay in transplant age has occurred in the United States for Alport patients across all racial/et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60621217ae55f23004346bac2657ce4a
https://pubmed.ncbi.nlm.nih.gov/34642018
https://pubmed.ncbi.nlm.nih.gov/34642018
Autor:
Clifford E. Kashtan
Publikováno v:
Advances in chronic kidney disease. 29(3)
Recent trends in the diagnosis, treatment, and classification of collagen IV-associated kidney disease are likely to result in increasing numbers of people in adult nephrology practices who have a confirmed diagnosis of Alport syndrome. These trends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b942dbe49ead27077033f57cdfb9e75e
https://pubmed.ncbi.nlm.nih.gov/36084969
https://pubmed.ncbi.nlm.nih.gov/36084969
Autor:
Clifford E. Kashtan
Publikováno v:
Future Rare Diseases. 1
Alport syndrome is a relatively rare but important genetic cause of progressive kidney disease, sensorineural deafness and ocular abnormalities. Alport syndrome arises from genetic variants in the COL4A3, COL4A4 and COL4A5 genes, resulting in abnorma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a44d8d7e45cb2f624dec3ae6cf20eeb9
https://doi.org/10.2217/frd-2021-0001
https://doi.org/10.2217/frd-2021-0001
Autor:
Andrew C. Nelson, Youngki Kim, Avi Katz, Mary Ella M Pierpont, Judy Chen, Clifford E. Kashtan, Lihong Bu
Publikováno v:
Kidney International Reports
Alport syndrome (AS) is a hereditary nephritis caused by mutations in COL4A3, COL4A4, and COL4A5, which encode the collagen IV alpha3, alpha4, and alpha5 chains, respectively.1 The collagen IV alpha345 molecule is the major component of the mature gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de25877252fffca912e2817ab7a977a
http://europepmc.org/articles/PMC6609819
http://europepmc.org/articles/PMC6609819
Autor:
Kenneth Lieberman, Clifford E. Kashtan, Vimal Chadha, Angie Goldsberry, Bradley A. Warady, Keisha L. Gibson, Rasheed A Gbadagesin, Kevin E.C. Meyers, Kandai Nozu, Debbie S. Gipson, Colin J. Meyer, Melanie Chin, Megan O'Grady, Michelle N. Rheault
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Alport syndrome is a genetic disease accounting for an estimated 3% of children with end-stage kidney disease (ESKD) in the US (USRDS, 2014). Current management recommendations include the use of renin-angiotensin-aldosterone syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::208538010f2fbd87b348c11b97990352
https://doi.org/10.1093/ndt/gfab133.003
https://doi.org/10.1093/ndt/gfab133.003